AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26968269
Drug: Nebulised salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulised salbutamol with ipratropium bromide (250 ug/dose)
Trial: 25224654
Drug: Steroid-eluting bioabsorbable
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-eluting bioabsorbable implant placed in the office after ESS
Trial: 25224654
Drug: Steroid-eluting bioabsorbable
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-eluting bioabsorbable implant
Trial: 22785573
Drug: Amlodipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine combination regimen
Trial: 19288975
Drug: Riluzole (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (100-200 mg/d)
Trial: 17694684
Drug: Supplemental magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental magnesium infusion (2 g after induction of anesthesia, then 8 g upon arrival in ICU until 24 hr)
Trial: 16979991
Drug: MMF 1.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 1.35 +/- 0.23 g/d (group 1)
Trial: 16979991
Drug: MMF 2
RxNorm normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF 2 g/d (group 2)
Trial: 10563400
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g meropenem tds
Trial: 10563400
Drug: amikacin 15
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: amikacin 15 mg/kg single dose daily plus ceftazidime 2 g tds
Trial: 8894145
Drug: Pamidronate disodium
RxNorm normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate disodium (120 mg for Group I, 180 mg for Group II, 240 mg for Group III) with daily infusions of either 30 mg or 60 mg for 2 years.
Trial: 8894145
Drug: Pamidronate disodium
RxNorm normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate disodium (60 mg infusions) for 2 years.
Trial: 8894145
Drug: Pamidronate disodium
RxNorm normalized name: Pamidronate Disodium
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate disodium treatment.
Trial: 6395060
Drug: Silicone sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone sponge soaked in antibiotic solution for at least 30 minutes prior to insertion
Trial: 6395060
Drug: Silicone sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone sponge not soaked in antibiotic solution
Trial: 26703193
Drug: Intravenous Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Tranexamic Acid (IV TXA) 2 g
Trial: 26703193
Drug: Topical Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Tranexamic Acid (Topical TXA) 2 g
Trial: 26703193
Drug: Topical Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Tranexamic Acid (Topical TXA)
Trial: 26703193
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and Topical Tranexamic Acid
Trial: 25234206
Drug: Blood-pressure-lowering treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood-pressure-lowering treatment (perindopril and indapamide)
Trial: 22072050
Drug: Adjuvant radioactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radioactive iodine treatment
Trial: 22072050
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant radioactive iodine treatment
Trial: 19284641
Drug: Hyperbaric treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric treatment at 1.3 atm and 24% oxygen (treatment group, n = 33)
Trial: 17542615
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g dose of steamed red cabbage
Trial: 17542615
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g dose of steamed red cabbage
Trial: 27206914
Drug: 35% phosphoric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% phosphoric acid treatment
Trial: 11356211
Drug: Er‐YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er‐YAG laser treatment at 2Hz and 250mJ on dentin and 300mJ on enamel
Trial: 11356211
Drug: Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser treatment followed by acid etching
Trial: 7884663
Drug: Cabergoline tablets
RxNorm normalized name: Cabergoline Tablets
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline tablets (1‐mg single oral dose)
Trial: 7884663
Drug: Cabergoline solution
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline solution (1‐mg single oral dose)
Trial: 7884663
Drug: Cabergoline tablets
RxNorm normalized name: Cabergoline Tablets
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline tablets
Trial: 7884663
Drug: Cabergoline solution
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline solution
Trial: 7884663
Drug: Cabergoline tablets
RxNorm normalized name: Cabergoline Tablets
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline tablets vs solution
Trial: 2874821
Drug: Felodipine 5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5‐20 mg twice daily
Trial: 2874821
Drug: Hydralazine 25‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine 25‐100 mg twice daily
Trial: 26614823
Drug: Short-term oral
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term oral ranolazine 500-1000 mg twice daily for 2 weeks
Trial: 24783602
Drug: Counting group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counting group (patients instructed to count numbers backwards starting from 100 during propofol injection)
Trial: 24121454
Drug: Goshajinkigan (TJ-107)
RxNorm normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goshajinkigan (TJ-107) 7.5 g daily
Trial: 21148246
Drug: Prescribed dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed dietary phosphate restriction (≤ 870 mg, 871 to 999 mg, 1000 mg, 1001 to 2000 mg)
Trial: 11109471
Drug: Cesar therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cesar therapy
Trial: 11109471
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment by general practitioner
Trial: 29624254
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release nimesulide formulation
Trial: 29624254
Drug: Reference nimesulide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference nimesulide formulation
Trial: 26245847
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy with no additional training
Trial: 24673496
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg luseogliflozin
Trial: 24673496
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg luseogliflozin
Trial: 24673496
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg luseogliflozin
Trial: 24673496
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg luseogliflozin
Trial: 21566204
Drug: L‐NMMA (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (6.4 µmol/min)
Trial: 21566204
Drug: L‐NMMA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA in PGF(2α)‐preconstricted veins
Trial: 19142567
Drug: EPA&DHA (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA&DHA (daily DHA/EPA capsules)
Trial: 19142567
Drug: Fatty fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatty fish (150 g salmon, three times per week)
Trial: 19142567
Drug: Lean fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lean fish (150 g cod, three times per week)
Trial: 12623959
Drug: felodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felodipine (10 mg/d, n=14)
Trial: 12623959
Drug: lercanidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lercanidipine (10 mg/d, n=14)
Trial: 12623959
Drug: acute drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acute drug administration
Trial: 10519687
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of brief advice and health education literature
Trial: 8901795
Drug: 10.5 mg
RxNorm normalized name: pectin 10.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.5 mg pure acetylsalicylic acid
Trial: 8901795
Drug: 9.1 mg
RxNorm normalized name: menthol 9.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.1 mg salicylic acid
Trial: 1912752
Drug: Fixed (non-negotiable)
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed (non-negotiable) dose reduction schedule
Trial: 7120089
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg perphenazine tablet
Trial: 7120089
Drug: Two 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 8 mg perphenazine tablets
Trial: 7120089
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg amitriptyline tablet
Trial: 7120089
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg amitriptyline tablet with 10 mg amitriptyline and 4 mg perphenazine combination tablet
Trial: 7120089
Drug: Two combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two combination tablets (10 mg amitriptyline and 4 mg perphenazine each)
Trial: 28695660
Drug: Menthacarin (2×1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthacarin (2×1 capsule/day for 4 weeks)
Trial: 28695660
Drug: Placebo (2×1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2×1 capsule/day for 4 weeks)
Trial: 25544635
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in both anterior and posterior regions
Trial: 25544635
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in posterior region only
Trial: 12695241
Drug: Brimonidine twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brimonidine twice a day
Trial: 12695241
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of timolol and dorzolamide twice a day
Trial: 8690826
Drug: Fluvoxamine maleate
RxNorm normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvoxamine maleate (50-150 mg/day)
Trial: 8690826
Drug: Imipramine (80-240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (80-240 mg/day)
Trial: 6137978
Drug: suxamethonium 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 1 mg X kg‐1 in a single bolus followed by an infusion (group A)
Trial: 6137978
Drug: vecuronium 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.05 mg X kg‐1 (group B)
Trial: 6137978
Drug: vecuronium 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.06 mg X kg‐1 (group C)
Trial: 6137978
Drug: vecuronium 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.07 mg X kg‐1 (group D)
Trial: 26284720
Drug: Liraglutide (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (3.0 mg)
Trial: 24858158
Drug: Transrectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transrectal lidocaine gel (Group I)
Trial: 24858158
Drug: Intraprostatic lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraprostatic lidocaine injection with intra rectal gel (Group II)
Trial: 15590856
Drug: Triamcinolone injection
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone injection with nimesulide (200 mg for seven days)
Trial: 15590856
Drug: Triamcinolone injection
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone injection with placebo (for seven days)
Trial: 11593959
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (group or individual)
Trial: 11593959
Drug: Individual cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive-behavioral treatment
Trial: 9141548
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (CEE) therapy (0.625 mg daily)
Trial: 9141548
Drug: CEE in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE in combination with medroxyprogesterone acetate (2.5 mg daily)
Trial: 9141548
Drug: CEE in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE in combination with medroxyprogesterone acetate (10 mg daily on days 1-12)
Trial: 9141548
Drug: CEE in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE in combination with micronized progesterone (200 mg daily on days 1-12)
Trial: 9141548
Drug: CEE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE therapy
Trial: 3113291
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg butorphanol
Trial: 3113291
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg butorphanol
Trial: 29553843
Drug: Quince sauce
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quince sauce (QS) 10 mg after meals
Trial: 9587554
Drug: Alteplase and
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alteplase and heparin
Trial: 7943865
Drug: Combined bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined bolus injection of subnarcotic doses of sodium hydroxybutyrate and sodium thiopental
Trial: 3091055
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (ISDN) 10 mg three times daily
Trial: 3091055
Drug: Transdermal nitrate
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitrate (TN) one 10 cm2 patch daily
Trial: 3091055
Drug: Transdermal nitrate
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitrate (TN)
Trial: 25555450
Drug: Single i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. dose of MAPC (10 million cells/kg)
Trial: 25555450
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly for up to 5 doses of MAPC (1 or 5 million cells/kg)
Trial: 25555450
Drug: MAPC infusions
RxNorm normalized name: Multipotent Adult Progenitor Cells (MAPCs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAPC infusions
Trial: 23766098
Drug: Liquid OLE
RxNorm normalized name: limonen-10-ol, (+)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid OLE (76.6 mg oleuropein, 14.5 mg hydroxytyrosol)
Trial: 23766098
Drug: Capsulated OLE
RxNorm normalized name: limonen-10-ol, (+)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsulated OLE (76.6 mg oleuropein, 14.5 mg hydroxytyrosol)
Trial: 23766098
Drug: OLE (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLE (both formulations)
Trial: 19561152
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg o.d.
Trial: 15087635
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil with 6 ml/h background infusion
Trial: 15087635
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil with 9 ml/h background infusion
Trial: 15087635
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil without background infusion
Trial: 15087635
Drug: PCEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil (all groups)
Trial: 11834229
Drug: One tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of 750 microg levonorgestrel at time -12 h and one tablet at time 0 (Group A)
Trial: 11834229
Drug: One tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of 750 microg levonorgestrel at time 0 (Group B)
Trial: 11834229
Drug: One tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of 750 microg levonorgestrel at time -24 h and one tablet at time 0 (Group C)
Trial: 9926761
Drug: DBM+CS implant
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBM+CS implant
Trial: 8050452
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with 6 g of highly concentrated ethyl esters of EPA and DHA daily for 4 months.
Trial: 8050452
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with 6 g of corn oil daily for 4 months (Control).
Trial: 3390111
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiethylperazine (10 mg) and cimetidine (300 mg)
Trial: 3390111
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiethylperazine (10 mg), cimetidine (300 mg), and promethazine (25 mg)
Trial: 330575
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily intramuscular injection of sisomicin (160 mg)
Trial: 330575
Drug: Two daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two daily injections of sisomicin (80 mg)
Trial: 21661410
Drug: N‐butyl‐2‐cyanoacrylate injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐butyl‐2‐cyanoacrylate injection
Trial: 11740831
Drug: Beta-Blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-Blocker therapy
Trial: 10426663
Drug: PALA (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PALA (1250 mg/m2 daily x 5 every 4 weeks)
Trial: 10426663
Drug: SAM (streptozotocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAM (streptozotocin 400 mg/m2 IV daily x 5, doxorubicin 45 mg/m2 IV on day 1 and 22, methyl CCNU 60 mg/m2 orally on days 1 and 22 every 6 weeks)
Trial: 16939848
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (300 mg twice a day)
Trial: 16939848
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without vitamin E supplementation (Control)
Trial: 11916175
Drug: Amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (500 mg orally three times per day for 7 days)
Trial: 8072200
Drug: UFT (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (400 mg Tegafur plus 896 mg uracil/day)
Trial: 8072200
Drug: FT (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FT (800 mg/day)
Trial: 3178506
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4.5 g n‐3 PUFA's)
Trial: 30616614
Drug: Lesinurad 200
RxNorm normalized name: lesinurad 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 200 mg plus febuxostat
Trial: 30616614
Drug: Lesinurad 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 400 mg plus febuxostat
Trial: 30616614
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 mg (Control)